MYGN Insider Selling: Two Officers Dispose Shares April 16, 2026

Insider trading patterns reveal what company leaders really think about stock value. When executives sell shares, it often signals confidence concerns or portfolio rebalancing. On April 14, 2026, two senior officers at MYGN (Myriad Genetics, Inc.) disposed of shares in coordinated transactions. Chief Scientific Officer Dale Muzzey and Chief Operating Officer Mark Verratti both sold common stock on the same day. These insider sales totaled over 2,000 shares worth approximately $9,893. Understanding these insider transactions helps investors gauge executive sentiment about the company’s near-term direction.

Two Officers Sell MYGN Stock on Same Day

On April 14, 2026, two key executives at Myriad Genetics executed insider sales within hours of each other. Both transactions were filed with the SEC on April 15, 2026. These coordinated dispositions suggest planned, deliberate portfolio moves rather than reactive trades.

Chief Scientific Officer Dale Muzzey Disposes 946 Shares

Dale Muzzey, serving as Chief Scientific Officer, sold 946 shares of common stock at $4.91 per share. The transaction totaled approximately $4,644.86. After this sale, Muzzey retained 326,310 shares, maintaining substantial ownership in the company. The SEC filing shows this was classified as an F-InKind disposition, a standard form of stock disposal.

Chief Operating Officer Mark Verratti Sells 1,069 Shares

Mark Verratti, Chief Operating Officer, disposed of 1,069 shares at the identical price of $4.91 per share. His sale generated approximately $5,248.79 in proceeds. Following the transaction, Verratti held 629,646 shares, representing significant continued investment in MYGN. Like Muzzey’s trade, Verratti’s Form 4 filing documented the F-InKind disposition method.

Understanding the Insider Selling Pattern

Both officers sold shares at the exact same price on the same trading day. This uniformity suggests a planned, coordinated action rather than individual investment decisions. F-InKind transactions typically involve stock transfers or exercises tied to compensation plans, not discretionary market sales.

What F-InKind Dispositions Mean

F-InKind transactions represent a specific type of stock disposal often linked to equity compensation, tax withholding, or planned divestment strategies. These are not spontaneous market sells. Instead, they reflect predetermined corporate actions. Both Muzzey and Verratti used this method, indicating structured portfolio management. The identical $4.91 price point reinforces this was likely part of a coordinated company program.

Combined Insider Activity and Market Signal

Together, the two officers disposed of 2,015 shares worth approximately $9,893. While not massive in absolute terms, the coordinated timing and identical pricing carry significance. Both executives retained substantial holdings after the sales, showing continued confidence. Muzzey kept over 326,000 shares. Verratti maintained nearly 630,000 shares. This suggests the sales were routine portfolio adjustments, not panic selling.

What This Means for MYRIAD Genetics Investors

Insider transactions provide a window into executive sentiment about company prospects. These April 14 sales offer mixed signals worth analyzing carefully. The coordinated nature and retention of large positions suggest measured confidence, not alarm.

Executive Confidence Remains Strong

Both officers retained massive share counts after selling. Muzzey’s 326,310 remaining shares and Verratti’s 629,646 shares demonstrate deep personal investment in MYGN’s future. Executives who believe in their company typically hold significant equity stakes. These retention levels indicate leadership still backs the business direction. The sales appear routine, not indicative of major concerns.

Meyka AI Grade and Investor Context

Myriad Genetics carries a Meyka AI Grade of B, reflecting solid fundamentals and sector positioning. This grade factors in S&P 500 comparisons, financial growth metrics, and analyst consensus. The insider sales don’t contradict this assessment. Instead, they fit a pattern of normal executive portfolio management. Investors should monitor future insider activity for any shift in this pattern.

SEC Filing Details and Transparency

Both transactions were properly disclosed through Form 4 filings, the standard SEC document for insider trades. These filings ensure public transparency and regulatory compliance. All details are publicly available for investor review.

Form 4 Filing Requirements

Form 4 filings must be submitted within two business days of the transaction. Both Muzzey and Verratti’s trades were filed on April 15, 2026, meeting this deadline. The forms include transaction date, share count, price, and remaining holdings. This transparency allows investors to track executive activity in real time. The SEC maintains these records for public access and analysis.

Transaction Classification and Reporting

Both trades were classified as dispositions (sales) of common stock. The F-InKind method indicates these were likely tied to compensation or planned divestment programs. Neither officer reported any unusual circumstances. The transactions occurred at market prices, reflecting fair value exchange. All reporting followed standard SEC protocols and regulatory requirements.

Final Thoughts

On April 14, 2026, Myriad Genetics insiders executed coordinated stock sales totaling 2,015 shares worth $9,893. Chief Scientific Officer Dale Muzzey sold 946 shares, while Chief Operating Officer Mark Verratti disposed of 1,069 shares, both at $4.91 per share. These F-InKind transactions appear routine and planned rather than reactive. Both executives retained substantial holdings, signaling continued confidence in MYGN. The coordinated timing and identical pricing suggest structured portfolio management aligned with company programs. For investors, these insider sales carry neutral-to-positive signals, especially given the officers’ massive remaining equity stakes and MYGN’s solid Meyka…

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.